Skip to content

Study · Systematic review · 2022

1 result

A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art.

Cerami C, Perini G, Panzavolta A, Cotta Ramusino M, Costa A

International journal of molecular sciences30 Sept 2022Cited by 2 (Europe PMC)

PMID36232852 (opens in a new tab)PMCIDPMC9569533 (opens in a new tab)DOI10.3390/ijms231911550 (opens in a new tab)PepBankPUB-36232852
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Growing evidence supports the presence of social cognition deficits and social behavior alterations in major and minor neurocognitive disorders (NCDs). Even though the ability to identify socio-emotional changes has significantly improved in recent years, there is still no specific treatment available. Thus, we explored evidence of drug therapies targeting social cognition alterations in NCDs. Papers were selected according to PRISMA guidelines by searching on the PubMed and Scopus databases. Only papers reporting information on pharmacological interventions for the treatment of social cognition and/or social behavioral changes in major and/or minor NCDs were included. Among the 171 articles entered in the paper selection, only 9 papers were eligible for the scope of the review. Trials testing pharmacological treatments for socio-emotional alterations in NCDs are poor and of low-medium quality. A few attempts with neuroprotective, psychoactive, or immunomodulating drugs have been made. Oxytocin is the only drug specifically targeting the social brain that has been tested with promising results in frontotemporal dementia. Its beneficial effects in long-term use have yet to be evaluated. No recommendation can currently be provided. There is a long way to go to identify and test effective targets to treat social cognition changes in NCDs for the ultimate benefit of patients and caregivers.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of drug therapies for social cognition changes in neurocognitive disorders, oxytocin was tested with promising results in frontotemporal dementia.

    In plain wordsA review found that oxytocin gave promising results in frontotemporal dementia, but long-term benefit is not yet known and no recommendation can be made.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedSocial behavior in frontotemporal dementia
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oxytocin is the only drug specifically targeting the social brain that has been tested with promising results in frontotemporal dementia.
    2 context sentences
    Summary · context
    No recommendation can currently be provided.
    Summary · context
    Among the 171 articles entered in the paper selection, only 9 papers were eligible for the scope of the review.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.